Polypeptide and therapeutic uses thereof

A peptide compound of formula (VII) or a pharmaceutically acceptable salt or solvate thereof,

• Y-aib-E-G-T-F-X11-S-D-X1-S-X12-X2-L-X3-X4-E-A-X5-X6-X13-F-X7-X8-W-L-X9-A-G-X10 (VII) (SEQ ID NO:
• 220),
• wherein X1 is an amino acid selected from L or Y;
• X2 is an amino acid selected from Q, A, aib or Y;
• X3 is an amino acid selected from D or E;
• X4 is an amino acid selected from E or K;
• X5 is an amino acid selected from V or A;
• X6 is an amino acid selected from K or R;
• X7 is an amino acid selected from I or V;
• X8 is an amino acid selected from E or N;
• X9 is an amino acid selected from I or L;
• X10 is GPSSGAPPP (SEQ ID NO:
• 227), GPSSGA (SEQ ID NO:
• 232), or GPS (SEQ ID NO:
• 236);
• wherein one or two amino acids selected from serine, lysine or cysteine are added to the C-terminus of X10, and the carboxyl group of the C-terminal amino acid is optionally amidated to a C-terminal amide, optionally, the lysine or cysteine at the C-terminus of X10 contains a side chain which is modified with a long-acting group, wherein
• the long-acting group has the structure of formula (IV):
• O1-O2-O3-O4-O5-O6-O7-O8- (IV),
• wherein O1 has the structure of formula (V) or (VI):
• wherein n2 is an integer of 10-24;
• wherein the wavy line indicates the attachment point to the adjacent group, and O2-O3-O4-O5-O6-O7-O8- represents a linker, wherein each of O2 to O8 is independently selected from any one of the following amino acid residues or long chain structures:
• α-Glu, γ-Glu, α-Asp, β-Asp, α-hGlu, δ-hGlu, Gly, Ala, β-Ala, GABA or PEG2, or one or more residues O2 to O8 are absent, provided that at least two residues O2 to O8 are present, and O2 to O8 contain at least one negatively charged moiety;
• or X10 is absent;
• X11 is T;
• X12 is I;
• X13 is L.